Monocyte-derived macrophage and CAR-macrophage manufacturing —
selection, differentiation, transduction, and GMP release testing inside one organization.
Macrophage cell therapy manufacturing selects monocytes from apheresis material, engineers them — for CAR-macrophage (CAR-M) products, with a chimeric antigen receptor — and differentiates them into macrophages with a defined polarization state. Macrophages are attractive because they infiltrate solid tumors and present antigen, but they resist transduction and change phenotype during differentiation, so the order of engineering and differentiation is the central process decision.
GeneFab is a CDMO for GMP macrophage and CAR-macrophage manufacturing. We cover monocyte selection, myeloid-appropriate genetic circuit design, vector we manufacture ourselves so serotype and potency remain variables we can move, differentiation and polarization control, and function-based potency and GMP release testing.
Macrophage programs enter with a construct, a differentiation protocol, or a target. These are the pieces we own.
Leukapheresis and isolated PBMCs with monocyte selection strategy defined against the differentiation route. Material specifications and chain of identity are set during tech transfer.
CAR-macrophage architecture, promoter selection, and payload design from our synthetic biology group, with regulatory elements appropriate to myeloid cells and screening in primary cells.
Monocytes and macrophages are difficult to transduce. Vector we manufacture ourselves means serotype, potency, and transduction conditions are all variables we can move, with non-viral options where a vector is not the right tool.
Differentiation into the target macrophage phenotype, with polarization state treated as a controlled, measured product attribute — including its stability through formulation and freeze.
Closed wash, concentration, and cryopreservation into the final container, with post-thaw viability and retained phenotype treated as release-relevant.
Identity, purity, potency, and safety assays developed against the process, with core biosafety testing performed in house.
Transduce the monocyte or the differentiated macrophage? The answer changes your efficiency, your phenotype, and your release package — and it is only answerable empirically, with a vector you control.
Transduction before or after differentiation evaluated as a real process decision, in engineering runs, not on principle.
Phenotype treated as a measured product attribute with stability tracked through formulation and freeze.
Serotype, potency, and conditions are all ours to change, because we make the vector in the same organization.
What sponsors ask before choosing a CAR-macrophage CDMO for a macrophage program.
Yes. We manufacture macrophage and monocyte cell therapies under GMP, including CAR-macrophage products, along with the vector used to engineer them.
Because we manufacture the vector in the same organization, serotype, potency, and transduction conditions are all variables we can change, and non-viral delivery is available where a viral vector is not the right tool.
It depends on the program, and it is a decision we test in engineering runs rather than assume. The sequencing affects transduction efficiency, final phenotype, and the release package.
Polarization state is treated as a controlled, measured product attribute, with analytics developed alongside the differentiation process and stability tracked through formulation and cryopreservation.
Yes. Function-based potency assays are developed alongside the process, together with identity, purity, and safety testing. Core biosafety tests run in house.
A technical exchange under CDA, then a gap assessment of your process and analytics, a tech transfer plan, and engineering runs before GMP. Requesting a quote starts that conversation.
